Septra and Capillaritis - a phase IV clinical study of FDA data

Summary:

Capillaritis is reported as a side effect among people who take Septra (sulfamethoxazole; trimethoprim), especially for people who are male, 10-19 old, also take Prednisone, and have Kidney transplant rejection.

The phase IV clinical study analyzes which people have Capillaritis when taking Septra. It is created by eHealthMe based on reports of 9,928 people who have side effects when taking Septra from the FDA, and is updated regularly.

What is Septra?

Septra has active ingredients of sulfamethoxazole; trimethoprim. It is often used in urinary tract infection. eHealthMe is studying from 10,280 Septra users. Check the latest studies of Septra.

What is Capillaritis?

Capillaritis (inflamed capillaries under the skin) is found to be associated with 49 drugs and 130 conditions by eHealthMe. Check the latest studies of Capillaritis.

On Jul, 18, 2026

9,928 people reported to have side effects when taking Septra.
Among them, 30 people (0.3%) have Capillaritis.

Among these 30 people:

What is the gender of people who have Capillaritis when taking Septra? *

female: 0.0 %
male: 100 %

What is the age of people who have Capillaritis when taking Septra? *

What are other drugs people take besides Septra? *

What are other side effects people have besides Capillaritis? *

White Blood Cell Count Decreased: 20 people, 66.67%
Respiratory Rate Increased (excess breathing rate/min): 20 people, 66.67%
Blood Creatinine Increased: 20 people, 66.67%
Blood Pressure Diastolic Decreased: 20 people, 66.67%
Blood Pressure Systolic Decreased: 20 people, 66.67%
Cough: 20 people, 66.67%
Glomerulonephritis (a group of conditions that affect parts of the kidneys called glomeruli): 20 people, 66.67%
Headache (pain in head): 20 people, 66.67%
Heart Rate Increased: 20 people, 66.67%
Injury: 20 people, 66.67%

What are the existing conditions these people have? *

Transplant Rejection (a transplant material is not worked): 20 people, 66.67%
Kidney Transplant Rejection: 20 people, 66.67%
High Blood Pressure: 5 people, 16.67%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Septra and have Capillaritis?

- Check whether Capillaritis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Septra:

Septra (10,280 reports)

Capillaritis treatments and more:

Capillaritis (226 reports)

How severe was Capillaritis and when was it recovered:

Capillaritis in Septra

Expand to all the drugs that have ingredients of sulfamethoxazole; trimethoprim:

Capillaritis and drugs with ingredients of sulfamethoxazole; trimethoprim

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Septra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Capillaritis:

Capillaritis (49 drugs)

Browse all the conditions that are associated with Capillaritis:

Capillaritis (130 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sulfamethoxazole; trimethoprim (the active ingredients of Septra) and Septra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.